These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19811711)

  • 21. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive.
    O'Connell KJ; Osborne LM; Westhoff C
    Contraception; 2005 Nov; 72(5):323-7. PubMed ID: 16246655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Injectable contraception: what should the longest interval be for reinjections?
    Steiner MJ; Kwok C; Stanback J; Byamugisha JK; Chipato T; Magwali T; Mmiro F; Rugpao S; Sriplienchan S; Morrison C
    Contraception; 2008 Jun; 77(6):410-4. PubMed ID: 18477489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of weight, packed cell volume changes and menstrual pattern in Norplant implant acceptors in Ilorin, Nigeria.
    Balogun OR
    Niger J Clin Pract; 2007 Jun; 10(2):116-9. PubMed ID: 17902502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use.
    Burkman RT; Fisher AC; LaGuardia KD
    J Reprod Med; 2007 Nov; 52(11):1030-4. PubMed ID: 18161401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endometrial histology of Depomedroxyprogesterone acetate users: a pilot study.
    Thurman AR; Soper DE
    Infect Dis Obstet Gynecol; 2006; 2006():69402. PubMed ID: 17093355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Injected with controversy: sales and administration of injectable contraceptives in drug shops in Uganda.
    Stanback J; Otterness C; Bekiita M; Nakayiza O; Mbonye AK
    Int Perspect Sex Reprod Health; 2011 Mar; 37(1):24-9. PubMed ID: 21478085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age.
    Juliato CT; Fernandes A; Marchi NM; Castro S; Olivotti B; Bahamondes L
    Contraception; 2007 Oct; 76(4):282-6. PubMed ID: 17900438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and acceptability of injectable medroxyprogesterone. A comparison of 3-monthly and 6-monthly regimens.
    Castle WM; Sapire KE; Howard KA
    S Afr Med J; 1978 May; 53(21):842-5. PubMed ID: 694638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Documented Excessive Weight Gain Among Adolescent Girls and Young Women Using Depot Medroxyprogesterone Acetate.
    Jirakittidul P; Somyaprasert C; Angsuwathana S
    J Clin Med Res; 2019 May; 11(5):326-331. PubMed ID: 31019626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body weight and amenorrhea.
    Wentz AC
    Obstet Gynecol; 1980 Oct; 56(4):482-7. PubMed ID: 7422193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study.
    Goldstein J; Cushman M; Badger GJ; Johnson JV
    Fertil Steril; 2007 Jun; 87(6):1267-70. PubMed ID: 17336967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of endometriosis with depot medroxyprogesterone acetate: a preliminary experience.
    Arowojolu AO
    Afr J Med Med Sci; 2000 Mar; 29(1):55-8. PubMed ID: 11379470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implanon use in Thai women above the age of 35 years.
    Booranabunyat S; Taneepanichskul S
    Contraception; 2004 Jun; 69(6):489-91. PubMed ID: 15157794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contraceptive use and contraception type in women by body mass index category.
    Schraudenbach A; McFall S
    Womens Health Issues; 2009; 19(6):381-9. PubMed ID: 19879452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
    Guilbert ER; Brown JP; Kaunitz AM; Wagner MS; Bérubé J; Charbonneau L; Francoeur D; Gilbert A; Gilbert F; Roy G; Senikas V; Jacob R; Morin R
    Contraception; 2009 Mar; 79(3):167-77. PubMed ID: 19185668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.
    Sheng J; Zhang WY; Zhang JP; Lu D
    Contraception; 2009 Mar; 79(3):189-93. PubMed ID: 19185671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No bones about it--depot medroxyprogesterone acetate remains an excellent contraceptive option for adolescents.
    Rager KM
    J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):187-8. PubMed ID: 15970254
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
    Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
    Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis.
    Verma S; Liew A; Subramaniam M; Poon LY
    Aust N Z J Psychiatry; 2009 Sep; 43(9):812-7. PubMed ID: 19670054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.